Exploring genetic factors linked to cancer cachexia in pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the association between genomic polymorphisms and cancer cachexia in patients with pancreatic adenocarcinoma. It will involve a cohort of 100 patients who are either locally advanced unresectable or metastatic, with a focus on identifying biomarkers that contribute to cachexia, a significant complication affecting prognosis. Specimens such as blood or buccal swabs will be collected during clinical visits and analyzed for genetic variations and clinical factors. The study will also evaluate confounding factors like disease stage and treatment history to better understand their impact on cachexia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this study:

* Written informed consent and HIPAA authorization for release of personal health information by the subject in accordance with the practices of the Levine Cancer Institute and Atrium Health. NOTE: HIPAA authorization will be included in the informed consent.
* Male or female patients age ≥ 18 years at the time of consent
* Histological or cytological confirmation of pancreatic adenocarcinoma, with a diagnosis of locally advanced unresectable PDAC (LAPC) or metastatic pancreatic adenocarcinoma. LAPC is defined as per NCCN 16. Note: Subject can be enrolled at any time during their cancer course following histologic diagnosis.
* Able to provide a blood or buccal sample.

Exclusion Criteria:

* None

Where it's running

• Levine Cancer Institute
  Charlotte, North Carolina, United States Recruiting
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Kunal Kadakia, MD — Atrium Health Levine Cancer Institute
• Study coordinator: CynDavia McKoy
• Email: Cyndavia.Mckoy@advocatehealth.org
• Phone: 704-355-2000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS010 in advanced cancer with cachexia: safety and early signals in adults

  This study tests DS010 in adults with cancer and cachexia to see if it is safe and whether it might help with their condition.

  Recruiting at 4 sites Phase 1/2 Dartsbio Pharmaceuticals Ltd. · Concord West, New South Wales and 3 other locations · NCT07921576

• Hepatic artery infusion therapy for liver metastases after pancreatic/duodenal cancer surgery

  This study tests whether delivering chemotherapy directly to the liver via a pump can help people with pancreatic or duodenal cancer that has spread mainly to the liver after surgery and prior chemotherapy.

  Recruiting AdventHealth · Orlando, Florida · NCT07845617

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Spatial multi-omics and AI-based early warning for pancreatic cancer cachexia

  This study tests whether spatial multi-omics data can reveal how the tumor and body metabolism interact in pancreatic cancer cachexia and whether a multimodal AI model can predict cachexia early in adults with pancreatic ductal adenocarcinoma.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07670286

• THE-0504 in patients with solid tumors

  A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.

  Recruiting Phase 1 Thena Biotech S.r.l. · Rome, Lazio · NCT07646106

• Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics

  This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.

  Recruiting China Medical University, China · Shenyang, Liaoning · NCT07519837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.